The FibreGum Study - Changing the Course of Obesity in Children

Inclusion Criteria:

• Informed Consent according to International Conference on Harmonisation of TechnicalRequirements for Registration of Pharmaceuticals for Human Use/Good ClinicalPractice (ICH/GCP) regulations prior to any study specific procedures

• Obesity as determined by a BMI ≥97th percentile using the Swiss paediatric, age- andsex-matched growth charts

• Newly referred within the last month to a tertiary weight management clinic

• Participant willing to use the study specific monitoring app on his/her own or legalrepresentatives' smartphone

Exclusion Criteria:

• Antibiotic administration in the last 6 months

• Pre- or probiotic treatment in the last 6 weeks

• Any professionally supervised treatment for weight management within the last year

• Consumption of more than one nicotine product per month (e.g. cigarette, gum)

• Adolescent females: any stages of known pregnancy or lactation period

• Congenital disorder affecting the cardiovascular, hepatic or respiratory system in arelevant way (as per PI's or specialist's evaluation)

• Malignant disease on treatment or previous tumour affecting the appetite system (e.g., suprasellar, hypothalamic tumours)

• Systemic antibiotic or anti-inflammatory medication (e.g. systemic intake ofglucocorticoids) over the last 7 days

• Known eating disorder (medically diagnosed)

• Participation in another investigation with an investigational drug within the 30days preceding and during the present investigation

• Dependency from the sponsor or the clinical investigator

• Inability to follow the procedures of the investigation, e.g. due to languageproblems, psychological disorders, etc. of the participant and/or legalrepresentative